WO2017093370A1 - T-cell specific genome editing - Google Patents
T-cell specific genome editing Download PDFInfo
- Publication number
- WO2017093370A1 WO2017093370A1 PCT/EP2016/079370 EP2016079370W WO2017093370A1 WO 2017093370 A1 WO2017093370 A1 WO 2017093370A1 EP 2016079370 W EP2016079370 W EP 2016079370W WO 2017093370 A1 WO2017093370 A1 WO 2017093370A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell
- mammalian
- polynucleotide
- cells
- human
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 74
- 238000010362 genome editing Methods 0.000 title claims description 14
- 108091033409 CRISPR Proteins 0.000 claims abstract description 101
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 34
- 238000010354 CRISPR gene editing Methods 0.000 claims abstract description 32
- 210000004027 cell Anatomy 0.000 claims description 53
- 108020005004 Guide RNA Proteins 0.000 claims description 40
- 108091033319 polynucleotide Proteins 0.000 claims description 35
- 102000040430 polynucleotide Human genes 0.000 claims description 35
- 239000002157 polynucleotide Substances 0.000 claims description 35
- 239000013598 vector Substances 0.000 claims description 27
- 241000282414 Homo sapiens Species 0.000 claims description 24
- 239000002773 nucleotide Substances 0.000 claims description 19
- 125000003729 nucleotide group Chemical group 0.000 claims description 19
- 241001465754 Metazoa Species 0.000 claims description 15
- 230000009261 transgenic effect Effects 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 10
- 241001529936 Murinae Species 0.000 claims description 8
- 230000035772 mutation Effects 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 239000013603 viral vector Substances 0.000 claims description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 6
- 208000009869 Neu-Laxova syndrome Diseases 0.000 claims description 6
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 241000283690 Bos taurus Species 0.000 claims description 5
- 101150069832 CD2 gene Proteins 0.000 claims description 5
- 241000283073 Equus caballus Species 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 241000282465 Canis Species 0.000 claims description 4
- 241000282324 Felis Species 0.000 claims description 4
- 241000700159 Rattus Species 0.000 claims description 4
- 238000012217 deletion Methods 0.000 claims description 4
- 230000037430 deletion Effects 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 238000003780 insertion Methods 0.000 claims description 4
- 230000037431 insertion Effects 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 108020004705 Codon Proteins 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- 210000004602 germ cell Anatomy 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 208000009889 Herpes Simplex Diseases 0.000 claims description 2
- 108091081062 Repeated sequence (DNA) Proteins 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 230000001177 retroviral effect Effects 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 abstract description 12
- 230000001404 mediated effect Effects 0.000 abstract description 6
- 238000010363 gene targeting Methods 0.000 abstract description 4
- 238000002679 ablation Methods 0.000 abstract description 3
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 26
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 24
- 230000006870 function Effects 0.000 description 12
- 108091093088 Amplicon Proteins 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 6
- 108700019146 Transgenes Proteins 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000027455 binding Effects 0.000 description 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 108700028369 Alleles Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 230000024932 T cell mediated immunity Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000000287 oocyte Anatomy 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 3
- 238000010453 CRISPR/Cas method Methods 0.000 description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108010091086 Recombinases Proteins 0.000 description 3
- 102000018120 Recombinases Human genes 0.000 description 3
- 241000193996 Streptococcus pyogenes Species 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000012239 gene modification Methods 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000012301 transgenic model Methods 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 238000007857 nested PCR Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 230000003584 silencer Effects 0.000 description 2
- 238000007860 single-cell PCR Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 101150102092 ccdB gene Proteins 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/20—Animal model comprising regulated expression system
- A01K2217/206—Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific
Definitions
- the present invention is concerned with the field of genome editing.
- the invention provides CRISPR/Cas9 vectors and vector systems, wherein the Cas9 protein is under the control of a T cell specific promoter.
- the invention further provides the use of such vectors for targeted genome editing of T cells.
- a functioning immune system is central to the body's capability to fight off diseases caused by pathogens, but also to fight cancer. If the immune system in a body is weakened, diseases can easily develop. On the other hand, if the immune system is not working in a regulated way, it can attack its own cells, causing autoimmune diseases.
- the immune system comprises the innate immune system and the adaptive immune system, which each comprise both humoral and cell-mediated components.
- the humoral components comprise B cells, which produce soluble antibodies.
- the cell-mediated immunity comprises macrophages, natural killer cells and T cells.
- Cell-mediated immunity protects the body by activating antigen-specific cytotoxic T- lymphocytes that are able to induce apoptosis in body cells displaying epitopes of foreign antigen on their surface, such as virus-infected cells, cells with intracellular bacteria, and cancer cells displaying tumor antigens. Furthermore, macrophages and natural killer cells are activated, enabling them to destroy pathogens; cells involved in the immune system are also stimulated to secrete a variety of cytokines that influence the function of other cells involved in adaptive immune responses and innate immune responses.
- T cells are the CD8 + cytotoxic T cells, and the CD4 + T helper cells.
- T helper cells assist other white blood cells in immunologic processes, including maturation of B cells into plasma cells and memory B cells, and activation of cytotoxic T cells and macrophages. These cells are also known as CD4 + T cells because they express the CD4 glycoprotein on their surfaces.
- Cytotoxic T cells destroy virus-infected cells and tumor cells, and are also implicated in transplant rejection. These cells are also known as CD8 + T cells since they express the CD8 glycoprotein at their surfaces. These cells recognize their targets by binding to antigen associated with MHC class I molecules, which are present on the surface of all nucleated cells. Through IL-10, adenosine, and other molecules secreted by regulatory T cells, the CD8+ cells can be inactivated to an anergic state, which prevents autoimmune diseases.
- T cells are therefore essential components of the immune system whose malfunction or absence is central to multiple pathologies, including inborn and acquired immune deficiencies, autoimmunity and cancer.
- conditional gene targeting still relies on ES cells for introduction of the recombinase target sites (loxP sites). Further, mouse lines carrying a loxP-containing allele need to be combined with a Cre transgene to address target gene function. Altogether the minimal time for generation of such conditional mutants is beyond a year. Furthermore, there is the possibility that Cre itself has an effect on the cells, like it was shown in mast cells.
- Cre/loxP system is very time consuming, and also requires many test animals to obtain a valid in vivo model organisms to study gene functions, and has undesirable effect on the model organism, in which the gene functions are to be studied, there is still a need for a system and method that allow single-step direct analysis of gene function within a certain cell lineage circumventing the tedious gene targeting and crossing necessary for Cre/loxP- mediated conditional gene ablation.
- Fig. 1 is concerned with conditional gene editing.
- a scheme of conditional gene editing is shown.
- the nuclease is placed under control of a cell type or lineage specific promoter.
- the gRNA construct is driven by the ubiquitous U6 promoter. Both transgenes are co-injected into oocytes, and double- transgenic animals are analyzed for cell-type specific gene deletion and phenotype
- Fig. 2 shows the abrogation of CD2 expression on a small population of T cells in an analysis of PBMC of the indicated mouse strains by flow cytometry. Shown are live cells within a lymphocyte gate. CD4 and CD8 cells are gated on TCR3. The percentage of cells found within the marked gates of the dot plot analysis is shown.
- Fig. 3 shows single cell PCR analysis of the target region within the CD2 locus.
- Peripheral blood lymphocytes were surface stained for CD2, CD4, CD8 and CD19 and single cell sorted by flow cytometry.
- a 253 bp long region including the gRNA target was amplified by two rounds nested PCR. Obtained products were cloned in pGEM-T and pGEM-Teasy and sequenced
- Fig. 4 shows the analysis of cell death in Cas9 transgenic animals in PBMC of the indicated mouse strains by flow cytometry. Presented are cells lying in a lymphocyte gate. The percentage of cells found within the marked gates of the dot plot analysis are shown. Aqua live dead staining was used for cell death analysis.
- Fig. 5 shows a vector map of the vector CD4-DEPE-Cas9 as defined by SEQ ID NO: 1.
- Fig. 6 shows a vector map of the vector px330gRNA(CD2) as defined by SEQ ID NO: 2.
- the present invention is concerned with the provision of a modified CRISPR/Cas9 system that can be used to directly edit genes in specific cell lineages, similar to conditional mutagenesis by the Cre/loxP system.
- the modified CRISPR/Cas9 system of the present invention allows single-step direct analysis of gene function within a certain cell lineage and circumvents the tedious gene targeting and crossing necessary for Cre/loxP-mediated conditional gene ablation.
- the modified CRISPR/Cas9 system of the present invention allows rapid assessment of cell-type specific phenotypic changes in a time frame incomparable to classical conditional mutagenesis. Compared with modern analysis tools for single cells such an approach is extremely useful.
- the present invention provides a modified CRISPR/Cas9 system, which allows a T cell specific gene modification.
- the modified CRISPR/Cas9 system of the present invention provides several advantages to the methods of the prior art. For example, the time to generate the transgenic model organism is reduced tremendously as well as the numbers of model organisms to be modified, because one can directly choose the background strain from the beginning and no intercrossing of strains to obtain homozygosity is necessary. Furthermore, it has surprisingly been shown that in vivo application of the modified CRISPR/Cas9 system of the present invention for conditional gene editing was not leading to increased apoptosis, as Cas9 itself does not lead to apoptosis, which leads to a more reliable model organism.
- the modified CRISPR/Cas9 system of the present invention can therefore be used to abrogate gene function in vivo and can be a useful research tool enabling rapid analysis of gene function in T cells.
- the modified CRISPR/Cas9 system of the present invention is a vector system comprising one or more vectors comprising
- a first regulatory element operably linked to one or more nucleotide sequences encoding CRISPR-Cas system polynucleotide sequences comprising one or more guide RNAs (gRNA), wherein the gRNA comprises a guide sequence, a trans-activating cr (tracr) RNA, and a tracr mate sequence, wherein the one or more gRNAs hybridize with one or more target sequences in polynucleotide loci in a mammalian T cell,
- gRNA guide RNAs
- a second regulatory element operably linked to a nucleotide sequence encoding a Type II Cas9 protein
- components (a) and (b) are located on same or different vectors of the system; wherein the CRISPR-Cas9 system comprises two or more nuclear localization signals (NLSs),
- nucleotide sequence encoding a Type II Cas9 protein is under the control of a T cell specific promoter, such as a mammalian CD4 promoter; and
- the one or more gRNAs target the one or more polynucleotide loci in the mammalian T cell and the Cas9 protein cleaves the one or more polynucleotide loci, whereby the sequence of the one or more polynucleotide loci is modified.
- CRISPR/Cas consists of two key components: a "guide" RNA (gRNA) and a non-specific CRISPR-associated endonuclease (Cas).
- gRNA guide RNA
- Cas CRISPR-associated endonuclease
- the original CRISPR/Cas system from Streptococcus pyogenes has been modified for application in molecular biology and now relies on one protein, the endonuclease Cas9, combined with a 102 bp long guide RNA (gRNA) of which 20 bp determine the target sequence.
- the modifications to the Cas9 enzyme have extended the application of CRISPR/Cas to selectively activate or repress target genes, purify specific regions of DNA, and even image DNA in live cells using fluorescence microscopy.
- the Cas9 protein can also be codon optimized for expression in a human cell, for example the protein termed hSpCas9 (humanized Cas9 derived from S. pyogenes).
- hSpCas9 humanized Cas9 derived from S. pyogenes.
- the skilled person knows how to obtain a codon optimized protein for expression in a human cell.
- the gRNA is a short synthetic RNA composed of a "scaffold" sequence necessary for Cas9-binding and a user-defined ⁇ 20 nucleotide "spacer” or “targeting" sequence which defines the genomic target to be modified.
- the gRNA can be preferably formed by one RNA molecule.
- the two or more nuclear localization signals can be expressed with the nucleotide sequence encoding the Cas9 protein; or can be encoded on the vector comprising the nucleotide sequences encoding the gRNA.
- the NLSs are comprised in the vector comprising the nucleotide sequences encoding the gRNA.
- the genomic target to be edited by the CRISPR/Cas9 system can be any ⁇ 20 nucleotide DNA sequence, provided it meets two conditions. Firstly, the sequence has to be unique compared to the rest of the genome. Secondly, the target has to be present immediately upstream of a Protospacer Adjacent Motif (PAM). Online tools have been developed for designing functionally competent gRNAs (see e.g. crispr.mit.edu).
- the PAM sequence is absolutely necessary for target binding and the exact sequence is dependent upon the species of Cas9.
- the PAM sequence for Streptococcus pyogenes Cas9 is 5 -NGG-3'.
- the Cas9 protein and the gRNA form a riboprotein complex through interactions between the gRNA "scaffold" domain and surface-exposed positively- charged grooves on Cas9.
- Cas9 undergoes a conformational change upon gRNA binding that shifts the molecule from an inactive, non-DNA binding conformation, into an active DNA- binding conformation.
- the "spacer" sequence of the gRNA remains free to interact with target DNA.
- the Cas9-gRNA complex will bind any genomic sequence with a PAM, but the extent to which the gRNA spacer matches the target DNA determines whether Cas9 will cut. Once the Cas9-gRNA complex binds a putative DNA target, a "seed" sequence at the 3' end of the gRNA targeting sequence begins to anneal to the target DNA. If the seed and target DNA sequences match, the gRNA will continue to anneal to the target DNA in a 3' to 5' direction. Cas9 will only cleave the target if sufficient homology exists between the gRNA spacer
- the T cells to be modified can be comprised in a model organism.
- the model organism to be modified by the CRISPR/Cas9 system of the present invention can be a mammal.
- the model organism to be modified by the CRISPR/Cas9 system can be a mouse, a human, a rat, a cow, a pig, a horse, a cat, or a dog.
- the model organism is a mouse.
- the model organism can also be a chimeric organism.
- the model organism can be a mouse, which comprises human T cells.
- the genes to be modified are part of the human DNA comprised in the T cells, which are in turn comprised in the chimeric mouse.
- the mammalian T cell to be modified by the CRISPR/Cas9 system of the present invention can be a murine, human, bovine, equine, porcine, canine, feline, or rat cell, preferably a murine or human T cell.
- the modified CRISPR/Cas9 system of the present invention can also be used to edit the genome of a T cell comprised in a tissue in vitro.
- the model organism is the tissue, and comprises the T cell to be modified.
- the T cell specific promoter is preferably a mammalian CD4 promoter.
- the mammalian CD4 promoter of the present invention can be found in any kind of mammal, because the CD4 system is phylogenetically older than mammals.
- the CD4 promoter comprises a nucleotide sequence as defined by nucleotides at positions 4054 to 4470 of SEQ ID NO:1 .
- the T cell specific promoter of the present invention is a modified CD4 promoter, which is specific for CD8 + T cells and CD4 + T cells, because it lacks the silencer sequence, and can, be defined by nucleotides at positions 2262 to 4470 of SEQ ID NO:1 , which also includes enhancer sequences.
- the gRNA of the present invention which targets the polynucleotide locus or gene in the T cell to be modified is under control of a promoter.
- This promoter can show consistent strong expression across all mammalian cells.
- this promoter is the human U6 promoter.
- the human U6 promoter is defined by nucleotides at position 1 to 251 of SEQ ID NO:2.
- the promoter controlling the transcription of the gRNA can also be a cell or tissue specific promoter. This can further enhance the specificity of the cell or tissue specific gene editing obtainable with the system of the present invention.
- a "polynucleotide locus” is the specific location or position of a gene on a chromosome.
- the guided RNAs (gRNAs) of the present invention can hybridize to a polynucleotide sequence in a certain polynucleotide locus. This polynucleotide sequence is termed the "target sequence”.
- the vector system of the present invention can comprise several gRNAs, which hybridize with several different target sequences within the same polynucleotide locus. This results in a more efficient modification of the polynucleotide locus.
- the polynucleotide locus to be modified is the CD2 gene.
- exon 2 of CD2 comprises the targeted the polynucleotide locus.
- CD2 is an easily detectable surface marker found on all T cells and whose deficiency was reported to not introduce survival biases. Therefore, the disruption of CD2 expression is a good example to observer the efficiency of the cell specific gene modification of the present invention.
- modified CRISPR/Cas9 system of the present invention is suitable to genetically modify any kind of polynucleotide locus or gene in a mammalian T cell.
- the target polynucleotide locus or gene can be chosen by the person of skill in the art trying to study the effects of the genetic editing in a T cell.
- the one or more gRNAs hybridize with one or more target sequences in the same polynucleotide locus. This allows an increase of the effect of the CRISPR/Cas9 system mediated gene editing.
- the vectors comprised in the system of the present invention are preferably bacterial or viral vectors.
- the origin of the vector can however be chosen freely by the skilled person as longs as the vector is applicable to the CRISPR/Cas9 system.
- the viral vectors can be retroviral, lentiviral, adenoviral, adeno-associated or herpes simplex viral vectors, or other viral vectors known in the art.
- the present invention is also concerned with the use of the modified CRISPR/Cas9 system of the present invention for editing the genome of a mammalian T cell, wherein genome editing does not comprise a method of modifying the germline of a human being, and wherein genome editing does not comprise a method of treatment of the human or animal body.
- Methods for introducing the vectors of the system of the present invention into a model organism are known to the skilled person.
- the vector constructs can be co-injected into the pronuclei of oocytes mice and the offspring can be screened for transgenic founders by PCR (see Example 1 ).
- the vectors can also be fused to be one vector.
- the modified CRISPR/Cas9 system of the present invention can be used in a method of treatment of the human or animal body, or in a diagnostic method.
- the mammalian T cell to be edited can be a murine, human, bovine, equine, porcine, canine, feline, or rat, or other mammalian cell, preferably a murine or human T cell.
- the use of the modified CRISPR/Cas9 system of the present invention for editing the genome of a mammalian T cell can comprise modifying the sequence of a target polynucleotide in a mammalian T cell, modifying expression of a polynucleotide in a mammalian T cell, generating a model mammalian T cell comprising a mutated disease gene, knocking out a gene, amplifying a gene, or repairing a mutation associated with DNA repeat instability.
- modified CRISPR/Cas9 system of the present invention for editing the genome of a mammalian T cell can further comprise editing or repairing the cleaved target polynucleotide by inserting an exogenous template polynucleotide, wherein the editing or repairing results in a mutation comprising an insertion, deletion, or substitution of one or more nucleotides of the target polynucleotide.
- the modified CRISPR/Cas9 system of the present invention for editing the genome of a mammalian T cell can also be used in the production of a non-human transgenic animal.
- one further embodiment of the present invention is a non-human transgenic animal obtained by the use of the modified CRISPR/Cas9 system of the present invention for editing the genome of a mammalian T cell in the production of a non-human transgenic animal.
- mice transgenic for Cas9 under control of the CD4 promoter and for U6 promoter-driven gRNA targeting of the CD2 locus were generated.
- peripheral blood we found a small population of CD4+ and CD8+ T cells lacking expression of CD2 was found. Sequencing of the CD2 locus in single cells from this population revealed insertion and deletion mutations, which led to abrogation of expression.
- Cas9 was placed under control of a CD4 promoter, thus directing expression towards T cells (see Fig. 1 B).
- a gRNA expression cassette was placed under control of a U6 promoter and a target sequence directed towards exon 2 of CD2 (see Fig. 1 B) was introduced.
- CD2 is an easily detectable surface marker found on all T cells and whose deficiency was reported to not introduce survival biases. Therefore, the disruption of CD2 expression is a good example to observe the efficiency of the cell specific gene modification of the present invention.
- the two constructs were co-injected into the pronuclei of oocytes of FVB/N mice and offspring screened for transgenic founders by PCR. One transgenic founder carrying both constructs was identified (see Fig.
- CD2 locus was edited by CRISPR/Cas9
- the one founder presenting with T lymphocytes lacking CD2 single cells was sorted and a fragment around the target site after PCR amplification and cloning was sequenced (see Fig. 3A). It was observed that of nine CD2 " CD4 + T cells eight carried a single mutation in the amplicon (see Fig. 3B). Of the three amplicons from CD2 " CD8 + T cells two were wildtype and one mutated (see Fig. 3B). In all amplicons, only a single sequence was found, either mutated or wildtype.
- CD4-DEPE- Cas9 was PCR-amplified and placed into the second exon of CD4 in a construct (CD4- DEPE) consisting of the CD4 promoter, the distal and the proximal enhancer, exon 1 and parts of exon 2 but lacking the intronic silencer.
- the resulting vector was termed CD4-DEPE- Cas9 (see Fig. 5) and is defined by the nucleotide sequence of SEQ ID NO:1 .
- the CD4 promoter is specific for CD8 + T cells and CD4 + T cells and is defined by nucleotides at positions 4054 to 4470 of SEQ ID NO:1. Subsequently, the plasmid was digested with Notl.
- the protospacer specific for exon 2 of CD2 (5'-GACTAGGCTGGAGAAGGACC-3'(SEQ ID NO:3)) was cloned with Bbsl into a modified px330 vector (px330ccdBChR), thus replacing a ccdB/chloramphenicol cassette.
- the resulting vector was termed px330gRNA(CD2) (see Fig. 6) and is defined by the nucleotide sequence of SEQ ID NO:2.
- the human U6 promoter is defined by nucleotides at position 1 to 251 of SEQ ID NO:2.
- the transgene was cut out by BciVI and Xbal. Both constructs were injected into FVB/N oocytes.
- the founders were screened by PCR using following primers: CD4 Cas9 typ fwd: 5'-TGC TCA CAA CCC TTT AGT TT-3' (SEQ ID NO:4), CD4 Cas9 typ rev: 5'-CTT TTT ATC CTC CTC CAC C-3' (SEQ ID NO:5) (product length: 835 bp); U6 fwd: 5'-GAG GGC CTA TTT CCC ATG ATT CC-3' (SEQ ID NO:6), T7 gRNA rev: 5'-GCA CGC GCT AAA AAC GGA-3' (SEQ ID NO:7) (product length: 407 bp). Animals were kept in barrier-SPF level animal facilities at Technische Universitat Munchen according to German law.
- Blood samples were treated with red blood cell lysis buffer (REF) and washed with PBS. They were stained in FACS buffer (REF) with following antibodies: anti-CD2 FITC, anti-TCR3 PE, anti-CD8 PerCP, anti-CD19 APC and anti-CD4 PB (all Biolegend). Live/Dead discrimination was performed by propidium iodide or Live Dead Fixable Aqua Dead Cell Stain Kit (life technologies). Single cells were sorted (BD, MoFlow) onto AmpliGrid slides and processed immediately. Cells were acquired at BD Canto II analysed with FlowJo Version 9.4.
- PCRs were performed with following primers: out fwd: 5'-ATC ACC CTG AAC ATC CCC AAC-3' (SEQ ID NO:8), out rev: 5'-ACT GGA GTC TTC TTG TGG GC-3' (SEQ ID NO:9) (product length: 382 bp); in fwd: 5'-CTG GTC GCA GAG TTT AAA AGG-3' (SEQ ID NO:10), in rev: 5'-GCT GCT CCC CAA CTT TCT AC-3' (SEQ ID N0:1 1 ) (product length 253 bp).
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Molecular Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention is concerned with the provision of a modified CRISPR/Cas9 system that can be used to directly edit genes in T cells. The modified CRISPR/Cas9 system of the present invention allows single-step direct analysis of gene function within Tcells lineage and circumvents the tedious gene targeting and crossing necessary for Cre/loxP-mediated conditional gene ablation.
Description
T cell specific genome editing
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
Field of the invention
The present invention is concerned with the field of genome editing. The invention provides CRISPR/Cas9 vectors and vector systems, wherein the Cas9 protein is under the control of a T cell specific promoter. The invention further provides the use of such vectors for targeted genome editing of T cells.
Background
A functioning immune system is central to the body's capability to fight off diseases caused by pathogens, but also to fight cancer. If the immune system in a body is weakened, diseases can easily develop. On the other hand, if the immune system is not working in a regulated way, it can attack its own cells, causing autoimmune diseases. The immune system comprises the innate immune system and the adaptive immune system, which each comprise both humoral and cell-mediated components. The humoral components comprise B cells, which produce soluble antibodies. The cell-mediated immunity comprises macrophages, natural killer cells and T cells.
Cell-mediated immunity protects the body by activating antigen-specific cytotoxic T- lymphocytes that are able to induce apoptosis in body cells displaying epitopes of foreign antigen on their surface, such as virus-infected cells, cells with intracellular bacteria, and cancer cells displaying tumor antigens. Furthermore, macrophages and natural killer cells are activated, enabling them to destroy pathogens; cells involved in the immune system are also stimulated to secrete a variety of cytokines that influence the function of other cells involved in adaptive immune responses and innate immune responses.
Cell-mediated immunity is directed primarily at microbes that survive in phagocytes and microbes that infect non-phagocytic cells. It is most effective in removing virus-infected cells, but also participates in defending against fungi, protozoans, cancers, and intracellular bacteria. It also plays a major role in transplant rejection.
Very important components of the cell-mediated immunity are the T cells. Among the T cells are the CD8+ cytotoxic T cells, and the CD4+ T helper cells. T helper cells assist other white blood cells in immunologic processes, including maturation of B cells into plasma cells and memory B cells, and activation of cytotoxic T cells and macrophages. These cells are also known as CD4+ T cells because they express the CD4 glycoprotein on their surfaces.
Cytotoxic T cells (CTLs) destroy virus-infected cells and tumor cells, and are also implicated in transplant rejection. These cells are also known as CD8+ T cells since they express the CD8 glycoprotein at their surfaces. These cells recognize their targets by binding to antigen associated with MHC class I molecules, which are present on the surface of all nucleated cells. Through IL-10, adenosine, and other molecules secreted by regulatory T cells, the CD8+ cells can be inactivated to an anergic state, which prevents autoimmune diseases.
T cells are therefore essential components of the immune system whose malfunction or absence is central to multiple pathologies, including inborn and acquired immune deficiencies, autoimmunity and cancer.
Their important role in widespread diseases such as cancer, HIV, rheumatoid arthritis, and multiple sclerosis makes it necessary to intensely study T cells and their functions in in vivo models.
One approach to study the function of cells in vivo involves genome modification, wherein the effects of silencing or activating a gene can be observed in a model organism. Since 1987 targeted mutagenesis in the mouse was performed by manipulating embryonic stem (ES) cells in vitro. These were used to generate chimeric mice and through participation in the germline the cells could transmit their genetic information, thus founding a new, manipulated mouse line. As extension to this technology recombinases such as Cre/loxP or similar systems are frequently used to overcome lethality, to make inducible and cell-type specific knockouts or transgenes, or to remove antibiotic resistance genes. While widening the scope of the technology recombinase-mediated conditional gene targeting still relies on ES cells for introduction of the recombinase target sites (loxP sites). Further, mouse lines carrying a loxP-containing allele need to be combined with a Cre transgene to address target gene function. Altogether the minimal time for generation of such conditional mutants is beyond a year. Furthermore, there is the possibility that Cre itself has an effect on the cells, like it was shown in mast cells.
As the Cre/loxP system is very time consuming, and also requires many test animals to obtain a valid in vivo model organisms to study gene functions, and has undesirable effect on
the model organism, in which the gene functions are to be studied, there is still a need for a system and method that allow single-step direct analysis of gene function within a certain cell lineage circumventing the tedious gene targeting and crossing necessary for Cre/loxP- mediated conditional gene ablation.
It was therefore the problem to be solved by the present invention to provide a system for time-efficient and reliable editing of the genome of T cells to obtain a model for studying conditions and diseases associated with T cells. It was a further problem to be solved by the present invention to provide an animal model for studying conditions and diseases associated with T cells, wherein the number of animals required to obtain the model is reduced when compared to prior art methods.
Description of drawings
The invention is also explained with reference to the following figures.
Fig. 1 is concerned with conditional gene editing.
In a) a scheme of conditional gene editing is shown. In the Cas9 driver the nuclease is placed under control of a cell type or lineage specific promoter. The gRNA construct is driven by the ubiquitous U6 promoter. Both transgenes are co-injected into oocytes, and double- transgenic animals are analyzed for cell-type specific gene deletion and phenotype
In b) a PCR analysis of tail biopsies for presence of the CD4dsCas9 transgene (835 bp fragment) is shown.
In c) a PCR analysis of tail biopsies for the presence of the U6gRNA(CD2) transgene by
PCR (407 bp fragment) is shown.
Fig. 2 shows the abrogation of CD2 expression on a small population of T cells in an analysis of PBMC of the indicated mouse strains by flow cytometry. Shown are live cells within a lymphocyte gate. CD4 and CD8 cells are gated on TCR3. The percentage of cells found within the marked gates of the dot plot analysis is shown.
Fig. 3 shows single cell PCR analysis of the target region within the CD2 locus. Peripheral blood lymphocytes were surface stained for CD2, CD4, CD8 and CD19 and single cell sorted by flow cytometry. A 253 bp long region including the gRNA target was amplified by two rounds nested PCR. Obtained products were cloned in pGEM-T and pGEM-Teasy and sequenced
In a) an agarose gel showing PCR products of single cell amplicons of the target region within the CD2 gene locus from sorted peripheral blood single cells is shown.
In b) a table showing the number of amplicons obtained from the indicated sorted cell types and the frequency of obtained mutations is shown.
In c) an alignment of the obtained sequences from the CD2 gene amplicon is shown. Indicated is the cell type (right side) and frequency (left side) of the respective sequence.
Fig. 4 shows the analysis of cell death in Cas9 transgenic animals in PBMC of the indicated mouse strains by flow cytometry. Presented are cells lying in a lymphocyte gate. The percentage of cells found within the marked gates of the dot plot analysis are shown. Aqua live dead staining was used for cell death analysis.
Fig. 5 shows a vector map of the vector CD4-DEPE-Cas9 as defined by SEQ ID NO: 1. Fig. 6 shows a vector map of the vector px330gRNA(CD2) as defined by SEQ ID NO: 2.
Description of the present invention
The present invention is concerned with the provision of a modified CRISPR/Cas9 system that can be used to directly edit genes in specific cell lineages, similar to conditional mutagenesis by the Cre/loxP system. The modified CRISPR/Cas9 system of the present invention allows single-step direct analysis of gene function within a certain cell lineage and circumvents the tedious gene targeting and crossing necessary for Cre/loxP-mediated conditional gene ablation. The modified CRISPR/Cas9 system of the present invention allows rapid assessment of cell-type specific phenotypic changes in a time frame incomparable to classical conditional mutagenesis. Compared with modern analysis tools for single cells such an approach is extremely useful.
To be able to study the gene functions of T cells in vivo, or in vitro, the present invention provides a modified CRISPR/Cas9 system, which allows a T cell specific gene modification.
It has been surprisingly found that by using the modified CRISPR/Cas9 system of the present invention, wherein Cas9 is under the control of a T cell specific promoter such as a CD4 promoter, and the gRNA targeting the gene to be modified is under the control of promoter, which shows consistent strong expression across all mammalian cells, a transgenic model organism could be generated, wherein the T cells of the transgenic model organism comprised the gene modified by the CRISPR/Cas9 system.
With the modified CRISPR/Cas9 system of the present invention, several advantages to the methods of the prior art are provided. For example, the time to generate the transgenic model organism is reduced tremendously as well as the numbers of model organisms to be modified, because one can directly choose the background strain from the beginning and no intercrossing of strains to obtain homozygosity is necessary.
Furthermore, it has surprisingly been shown that in vivo application of the modified CRISPR/Cas9 system of the present invention for conditional gene editing was not leading to increased apoptosis, as Cas9 itself does not lead to apoptosis, which leads to a more reliable model organism. The modified CRISPR/Cas9 system of the present invention can therefore be used to abrogate gene function in vivo and can be a useful research tool enabling rapid analysis of gene function in T cells.
The modified CRISPR/Cas9 system of the present invention is a vector system comprising one or more vectors comprising
a first regulatory element operably linked to one or more nucleotide sequences encoding CRISPR-Cas system polynucleotide sequences comprising one or more guide RNAs (gRNA), wherein the gRNA comprises a guide sequence, a trans-activating cr (tracr) RNA, and a tracr mate sequence, wherein the one or more gRNAs hybridize with one or more target sequences in polynucleotide loci in a mammalian T cell,
a second regulatory element operably linked to a nucleotide sequence encoding a Type II Cas9 protein,
wherein components (a) and (b) are located on same or different vectors of the system; wherein the CRISPR-Cas9 system comprises two or more nuclear localization signals (NLSs),
wherein the nucleotide sequence encoding a Type II Cas9 protein is under the control of a T cell specific promoter, such as a mammalian CD4 promoter; and
wherein the one or more gRNAs target the one or more polynucleotide loci in the mammalian T cell and the Cas9 protein cleaves the one or more polynucleotide loci, whereby the sequence of the one or more polynucleotide loci is modified.
The essential components of a classical CRISPR/Cas9 system are known to the person of skill in the art.
CRISPR/Cas consists of two key components: a "guide" RNA (gRNA) and a non-specific CRISPR-associated endonuclease (Cas). The original CRISPR/Cas system from Streptococcus pyogenes has been modified for application in molecular biology and now relies on one protein, the endonuclease Cas9, combined with a 102 bp long guide RNA (gRNA) of which 20 bp determine the target sequence. The modifications to the Cas9 enzyme have extended the application of CRISPR/Cas to selectively activate or repress target genes, purify specific regions of DNA, and even image DNA in live cells using fluorescence microscopy. The Cas9 protein can also be codon optimized for expression in a
human cell, for example the protein termed hSpCas9 (humanized Cas9 derived from S. pyogenes). The skilled person knows how to obtain a codon optimized protein for expression in a human cell.
The gRNA is a short synthetic RNA composed of a "scaffold" sequence necessary for Cas9-binding and a user-defined ~20 nucleotide "spacer" or "targeting" sequence which defines the genomic target to be modified. Thus, the skilled person can change the genomic target of Cas9 by simply changing the targeting sequence present in the gRNA. The gRNA can be preferably formed by one RNA molecule.
The two or more nuclear localization signals (NLSs) can be expressed with the nucleotide sequence encoding the Cas9 protein; or can be encoded on the vector comprising the nucleotide sequences encoding the gRNA. In a preferred embodiment the NLSs are comprised in the vector comprising the nucleotide sequences encoding the gRNA.
The genomic target to be edited by the CRISPR/Cas9 system can be any ~20 nucleotide DNA sequence, provided it meets two conditions. Firstly, the sequence has to be unique compared to the rest of the genome. Secondly, the target has to be present immediately upstream of a Protospacer Adjacent Motif (PAM). Online tools have been developed for designing functionally competent gRNAs (see e.g. crispr.mit.edu).
The PAM sequence is absolutely necessary for target binding and the exact sequence is dependent upon the species of Cas9. The PAM sequence for Streptococcus pyogenes Cas9 is 5 -NGG-3'. Once expressed, the Cas9 protein and the gRNA form a riboprotein complex through interactions between the gRNA "scaffold" domain and surface-exposed positively- charged grooves on Cas9. Cas9 undergoes a conformational change upon gRNA binding that shifts the molecule from an inactive, non-DNA binding conformation, into an active DNA- binding conformation. Importantly, the "spacer" sequence of the gRNA remains free to interact with target DNA. The Cas9-gRNA complex will bind any genomic sequence with a PAM, but the extent to which the gRNA spacer matches the target DNA determines whether Cas9 will cut. Once the Cas9-gRNA complex binds a putative DNA target, a "seed" sequence at the 3' end of the gRNA targeting sequence begins to anneal to the target DNA. If the seed and target DNA sequences match, the gRNA will continue to anneal to the target DNA in a 3' to 5' direction. Cas9 will only cleave the target if sufficient homology exists between the gRNA spacer
The T cells to be modified can be comprised in a model organism. The model organism to be modified by the CRISPR/Cas9 system of the present invention can be a mammal. For example the model organism to be modified by the CRISPR/Cas9 system can be a mouse, a
human, a rat, a cow, a pig, a horse, a cat, or a dog. Preferably, the model organism is a mouse. The model organism can also be a chimeric organism. For example, the model organism can be a mouse, which comprises human T cells. In this embodiment, the genes to be modified are part of the human DNA comprised in the T cells, which are in turn comprised in the chimeric mouse. Therefore the mammalian T cell to be modified by the CRISPR/Cas9 system of the present invention can be a murine, human, bovine, equine, porcine, canine, feline, or rat cell, preferably a murine or human T cell.
The modified CRISPR/Cas9 system of the present invention can also be used to edit the genome of a T cell comprised in a tissue in vitro. In this embodiment, the model organism is the tissue, and comprises the T cell to be modified.
The T cell specific promoter is preferably a mammalian CD4 promoter. The mammalian CD4 promoter of the present invention can be found in any kind of mammal, because the CD4 system is phylogenetically older than mammals. In a preferred embodiment, the CD4 promoter comprises a nucleotide sequence as defined by nucleotides at positions 4054 to 4470 of SEQ ID NO:1 . In a more preferred embodiment, the T cell specific promoter of the present invention is a modified CD4 promoter, which is specific for CD8+ T cells and CD4+ T cells, because it lacks the silencer sequence, and can, be defined by nucleotides at positions 2262 to 4470 of SEQ ID NO:1 , which also includes enhancer sequences.
The gRNA of the present invention, which targets the polynucleotide locus or gene in the T cell to be modified is under control of a promoter. This promoter can show consistent strong expression across all mammalian cells. In a preferred embodiment this promoter is the human U6 promoter. The human U6 promoter is defined by nucleotides at position 1 to 251 of SEQ ID NO:2. The promoter controlling the transcription of the gRNA can also be a cell or tissue specific promoter. This can further enhance the specificity of the cell or tissue specific gene editing obtainable with the system of the present invention.
A "polynucleotide locus" (plural loci) is the specific location or position of a gene on a chromosome. The guided RNAs (gRNAs) of the present invention can hybridize to a polynucleotide sequence in a certain polynucleotide locus. This polynucleotide sequence is termed the "target sequence". The vector system of the present invention can comprise several gRNAs, which hybridize with several different target sequences within the same polynucleotide locus. This results in a more efficient modification of the polynucleotide locus. For example, if it is intended to disrupt (knock-down) the function of the gene at the polynucleotide locus, the same result can be achieved by editing different target sequences in the locus.
In one embodiment of the present invention the polynucleotide locus to be modified is the CD2 gene. In a preferred embodiment, exon 2 of CD2 comprises the targeted the polynucleotide locus. CD2 is an easily detectable surface marker found on all T cells and whose deficiency was reported to not introduce survival biases. Therefore, the disruption of CD2 expression is a good example to observer the efficiency of the cell specific gene modification of the present invention. It is however important to note, that the modified CRISPR/Cas9 system of the present invention is suitable to genetically modify any kind of polynucleotide locus or gene in a mammalian T cell. The target polynucleotide locus or gene can be chosen by the person of skill in the art trying to study the effects of the genetic editing in a T cell.
In one embodiment of the present invention, the one or more gRNAs hybridize with one or more target sequences in the same polynucleotide locus. This allows an increase of the effect of the CRISPR/Cas9 system mediated gene editing.
The vectors comprised in the system of the present invention are preferably bacterial or viral vectors. The origin of the vector can however be chosen freely by the skilled person as longs as the vector is applicable to the CRISPR/Cas9 system.
The viral vectors can be retroviral, lentiviral, adenoviral, adeno-associated or herpes simplex viral vectors, or other viral vectors known in the art.
The present invention is also concerned with the use of the modified CRISPR/Cas9 system of the present invention for editing the genome of a mammalian T cell, wherein genome editing does not comprise a method of modifying the germline of a human being, and wherein genome editing does not comprise a method of treatment of the human or animal body. Methods for introducing the vectors of the system of the present invention into a model organism are known to the skilled person. For example, the vector constructs can be co-injected into the pronuclei of oocytes mice and the offspring can be screened for transgenic founders by PCR (see Example 1 ). The vectors can also be fused to be one vector.
In another embodiment the modified CRISPR/Cas9 system of the present invention can be used in a method of treatment of the human or animal body, or in a diagnostic method. The mammalian T cell to be edited can be a murine, human, bovine, equine, porcine, canine, feline, or rat, or other mammalian cell, preferably a murine or human T cell.
The use of the modified CRISPR/Cas9 system of the present invention for editing the genome of a mammalian T cell can comprise modifying the sequence of a target
polynucleotide in a mammalian T cell, modifying expression of a polynucleotide in a mammalian T cell, generating a model mammalian T cell comprising a mutated disease gene, knocking out a gene, amplifying a gene, or repairing a mutation associated with DNA repeat instability.
The use of the modified CRISPR/Cas9 system of the present invention for editing the genome of a mammalian T cell can further comprise editing or repairing the cleaved target polynucleotide by inserting an exogenous template polynucleotide, wherein the editing or repairing results in a mutation comprising an insertion, deletion, or substitution of one or more nucleotides of the target polynucleotide.
The modified CRISPR/Cas9 system of the present invention for editing the genome of a mammalian T cell can also be used in the production of a non-human transgenic animal.
In this regard, one further embodiment of the present invention is a non-human transgenic animal obtained by the use of the modified CRISPR/Cas9 system of the present invention for editing the genome of a mammalian T cell in the production of a non-human transgenic animal.
Examples
Preferred embodiments of the invention are outlined in the following examples which should not be interpreted as restricting the scope or spirit of the invention.
Example 1 - Modified CRISPR/Cas9 system
Mice transgenic for Cas9 under control of the CD4 promoter and for U6 promoter-driven gRNA targeting of the CD2 locus were generated. In peripheral blood we found a small population of CD4+ and CD8+ T cells lacking expression of CD2 was found. Sequencing of the CD2 locus in single cells from this population revealed insertion and deletion mutations, which led to abrogation of expression.
Cas9 was placed under control of a CD4 promoter, thus directing expression towards T cells (see Fig. 1 B). In a second construct a gRNA expression cassette was placed under control of a U6 promoter and a target sequence directed towards exon 2 of CD2 (see Fig. 1 B) was introduced. CD2 is an easily detectable surface marker found on all T cells and whose deficiency was reported to not introduce survival biases. Therefore, the disruption of CD2 expression is a good example to observe the efficiency of the cell specific gene modification of the present invention. The two constructs were co-injected into the pronuclei of oocytes of FVB/N mice and offspring screened for transgenic founders by PCR. One transgenic founder carrying both constructs was identified (see Fig. 1 C). One founder
carrying solely the Cas9 construct and two founders carrying only the gRNA construct were also obtained. In the double-transgenic founder an analysis of peripheral blood by flow cytometry revealed populations of CD4+ and CD8+ cells lacking expression of CD2 (see Fig. 2). No such populations were found in wildtype controls as well as Cas9 and gRNA-single transgenic founders (see Fig. 2).
To confirm that the CD2 locus was edited by CRISPR/Cas9 the one founder presenting with T lymphocytes lacking CD2 single cells was sorted and a fragment around the target site after PCR amplification and cloning was sequenced (see Fig. 3A). It was observed that of nine CD2"CD4+ T cells eight carried a single mutation in the amplicon (see Fig. 3B). Of the three amplicons from CD2"CD8+ T cells two were wildtype and one mutated (see Fig. 3B). In all amplicons, only a single sequence was found, either mutated or wildtype. This may be either the result of a technical bias leading to amplification of only one allele or alternatively the outcome of repair of the second allele by homologous recombination using an already mutated donor allele. In all 17 amplicons from CD2+ T cells as well as nine amplicons from CD19+ B cells solely unmutated sequences were obtained (see Fig. 3B), thus indicating the specificity of the system of the present invention. Sequence analysis of the mutations found within the amplicons from CD2" T cells revealed deletions spanning up to 19 bp and insertions of one to four base pairs (see Fig. 3C).
Even though CD2" T cells were observed in a Cas9/gRNA double-transgenic situation, the number of such cells was surprisingly low. This may have been a specific result of this particular founder due to expression variegation. To rule out that the low number of transgenic cells was due to a general problem of the system of the present invention, the T cell compartments were further analyzed in the different transgenic mice. The ratio of CD4+TCR3+ and CD8+TCR3+ T to CD19+ B cells was found to be slightly increased in double-transgenic versus Cas9 single and gRNA transgenic animals (4.9% and 4.8% versus 8% and 1 .8% and 1 .4% versus 2.2%). Since expression of nucleases such as Cre recombinase were reported to lead to apoptosis in situations of high proliferative activity, CD4+ and CD8+ T cells were analyzed for cell death by Live/Dead Fixable Aqua Dead Cell Stain Kit. No evidence was found for an increased number of dead cells in the Cas9/gRNA double-transgenic situation compared to either Cas9 or gRNA single transgenic mice (see Fig. 4). Thus, there was no evidence for induction of apoptosis by continuous presence of gRNA and Cas9 in T cells. For rapid investigation of oncogenes and tumor suppressor genes the observed low editing frequency may even prove to be advantageous.
Example 2 - Animal Models
Cas9 was PCR-amplified and placed into the second exon of CD4 in a construct (CD4- DEPE) consisting of the CD4 promoter, the distal and the proximal enhancer, exon 1 and parts of exon 2 but lacking the intronic silencer. The resulting vector was termed CD4-DEPE- Cas9 (see Fig. 5) and is defined by the nucleotide sequence of SEQ ID NO:1 . The CD4 promoter is specific for CD8+ T cells and CD4+ T cells and is defined by nucleotides at positions 4054 to 4470 of SEQ ID NO:1. Subsequently, the plasmid was digested with Notl.
The protospacer specific for exon 2 of CD2 (5'-GACTAGGCTGGAGAAGGACC-3'(SEQ ID NO:3)) was cloned with Bbsl into a modified px330 vector (px330ccdBChR), thus replacing a ccdB/chloramphenicol cassette. The resulting vector was termed px330gRNA(CD2) (see Fig. 6) and is defined by the nucleotide sequence of SEQ ID NO:2. The human U6 promoter is defined by nucleotides at position 1 to 251 of SEQ ID NO:2. The transgene was cut out by BciVI and Xbal. Both constructs were injected into FVB/N oocytes. The founders were screened by PCR using following primers: CD4 Cas9 typ fwd: 5'-TGC TCA CAA CCC TTT AGT TT-3' (SEQ ID NO:4), CD4 Cas9 typ rev: 5'-CTT TTT ATC CTC CTC CAC C-3' (SEQ ID NO:5) (product length: 835 bp); U6 fwd: 5'-GAG GGC CTA TTT CCC ATG ATT CC-3' (SEQ ID NO:6), T7 gRNA rev: 5'-GCA CGC GCT AAA AAC GGA-3' (SEQ ID NO:7) (product length: 407 bp). Animals were kept in barrier-SPF level animal facilities at Technische Universitat Munchen according to German law.
Example 3 - Flow cytometry
Blood samples were treated with red blood cell lysis buffer (REF) and washed with PBS. They were stained in FACS buffer (REF) with following antibodies: anti-CD2 FITC, anti-TCR3 PE, anti-CD8 PerCP, anti-CD19 APC and anti-CD4 PB (all Biolegend). Live/Dead discrimination was performed by propidium iodide or Live Dead Fixable Aqua Dead Cell Stain Kit (life technologies). Single cells were sorted (BD, MoFlow) onto AmpliGrid slides and processed immediately. Cells were acquired at BD Canto II analysed with FlowJo Version 9.4.
Example 4 - Molecular Biology
Single cell PCR was performed as nested PCR. The outer PCR was performed with Advantage2 (Clontech) directly on the AmpliGrid slide. For the inner PCR Herculase II Fusion Enzyme with dNTP combos (Agilent) was used. PCRs were performed with following primers: out fwd: 5'-ATC ACC CTG AAC ATC CCC AAC-3' (SEQ ID NO:8), out rev: 5'-ACT GGA GTC TTC TTG TGG GC-3' (SEQ ID NO:9) (product length: 382 bp); in fwd: 5'-CTG
GTC GCA GAG TTT AAA AGG-3' (SEQ ID NO:10), in rev: 5'-GCT GCT CCC CAA CTT TCT AC-3' (SEQ ID N0:1 1 ) (product length 253 bp).
Claims
1 . Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-CRISPR associated (Cas) (CRISPR-Cas) vector system comprising one or more vectors comprising
a) a first regulatory element operably linked to one or more nucleotide sequences encoding CRISPR-Cas system polynucleotide sequences comprising one or more guide RNAs (gRNA), wherein the gRNA comprises a guide sequence, a trans- activating cr (tracr) RNA, and a tracr mate sequence, wherein the one or more gRNAs hybridize with one or more target sequences in polynucleotide loci in a mammalian T cell,
b) a second regulatory element operably linked to a nucleotide sequence encoding a Type II Cas9 protein,
wherein components (a) and (b) are located on the same or different vectors of the system; wherein the CRISPR-Cas system comprises two or more nuclear localization signals;
wherein the nucleotide sequence encoding a Type II Cas9 protein is under the control of a mammalian CD4 promoter; and
wherein the one or more gRNAs target the one or more polynucleotide loci in the mammalian T cell and the Cas9 protein cleaves the one or more polynucleotide loci, whereby the sequence of the one or more polynucleotide loci is modified.
2. The system of claim 1 , wherein the mammalian CD4 promoter is defined by nucleotides at positions 4054 to 4470 of SEQ ID NO:1 , or preferably by nucleotides at positions 2262 to 4470 of SEQ ID NO:1.
3. The system of claim 1 or 2, wherein the mammalian T cell is a murine, human, bovine, equine, porcine, canine, feline, or rat cell, preferably a murine or human T cell.
4. The system of any one of claims 1 to 3, wherein the one or more gRNAs hybridize with one or more target sequences in the same polynucleotide locus.
5. The system of any one of the preceding claims, wherein the polynucleotide locus is the CD2 gene in the mammalian T cell, wherein optionally the one or more guide RNA hybridize with exon 2 of the CD2 gene.
6. The system of any one of the preceding claims, wherein the vectors are bacterial or viral vectors.
7. The system of any one of the preceding claims, wherein the viral vectors are retroviral, lentiviral, adenoviral, adeno-associated or herpes simplex viral vectors.
8. The system of any one of the preceding claims, wherein the Cas9 protein is codon optimized for expression in a human or mouse or other mammalian cell.
9. Use of the system of any of claims 1 to 8 for editing the genome of a mammalian T cell, wherein genome editing does not comprise a method of modifying the germline of a human being, and wherein genome editing does not comprise a method of treatment of the human or animal body.
10. The use of claim 9, wherein the mammalian T cell is a murine, human, bovine, equine, porcine, canine, feline, or rat cell, preferably a murine or human T cell.
1 1 . The use of claim 9 or 10, wherein the genome editing comprises modifying the sequence of a target polynucleotide in a mammalian T cell, modifying expression of a polynucleotide in a mammalian T cell, generating a model mammalian T cell comprising a mutated disease gene, knocking out a gene, amplifying a gene, or repairing a mutation associated with DNA repeat instability.
12. The use of claim 9, wherein the use further comprises editing or repairing said cleaved target polynucleotide by inserting an exogenous template polynucleotide, wherein said editing or repairing results in a mutation comprising an insertion, deletion, or substitution of one or more nucleotides of said target polynucleotide.
13. Use of the system of any one of claims 1 to 8 in the production of a non-human transgenic animal.
14. Non-human transgenic animal obtained by the use of any one of claims 1 1 to 12.
15. In vitro method for editing the genome function of a mammalian T cell using the system of any one of claims 1 to 8, wherein optionally the T cell is comprised in a cell tissue.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15197843.4 | 2015-12-03 | ||
EP15197843 | 2015-12-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017093370A1 true WO2017093370A1 (en) | 2017-06-08 |
Family
ID=54843659
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2016/079370 WO2017093370A1 (en) | 2015-12-03 | 2016-12-01 | T-cell specific genome editing |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2017093370A1 (en) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9999671B2 (en) | 2013-09-06 | 2018-06-19 | President And Fellows Of Harvard College | Delivery of negatively charged proteins using cationic lipids |
US10113163B2 (en) | 2016-08-03 | 2018-10-30 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US10167457B2 (en) | 2015-10-23 | 2019-01-01 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US10465176B2 (en) | 2013-12-12 | 2019-11-05 | President And Fellows Of Harvard College | Cas variants for gene editing |
US10508298B2 (en) | 2013-08-09 | 2019-12-17 | President And Fellows Of Harvard College | Methods for identifying a target site of a CAS9 nuclease |
US10597679B2 (en) | 2013-09-06 | 2020-03-24 | President And Fellows Of Harvard College | Switchable Cas9 nucleases and uses thereof |
US10704062B2 (en) | 2014-07-30 | 2020-07-07 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
CN111909961A (en) * | 2020-08-21 | 2020-11-10 | 华侨大学 | CRISPR/Cas-mediated ATL cell gene editing vector and application thereof |
US10858639B2 (en) | 2013-09-06 | 2020-12-08 | President And Fellows Of Harvard College | CAS9 variants and uses thereof |
US11046948B2 (en) | 2013-08-22 | 2021-06-29 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
US11306324B2 (en) | 2016-10-14 | 2022-04-19 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
US11345932B2 (en) | 2018-05-16 | 2022-05-31 | Synthego Corporation | Methods and systems for guide RNA design and use |
US11447770B1 (en) | 2019-03-19 | 2022-09-20 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
US11912985B2 (en) | 2020-05-08 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014093635A1 (en) * | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
-
2016
- 2016-12-01 WO PCT/EP2016/079370 patent/WO2017093370A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014093635A1 (en) * | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
Non-Patent Citations (5)
Title |
---|
ELENA E PEREZ ET AL: "Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases", NATURE BIOTECHNOLOGY, vol. 26, no. 7, 29 June 2008 (2008-06-29), pages 808 - 816, XP055024363, ISSN: 1087-0156, DOI: 10.1038/nbt1410 * |
HUA GU ET AL: "DELETION OF A DNA POLYMERASE BETA GENE SEGMENT IN T CELLS USING CELL TYPE TYPE-SPECIFIC GENE TARGETING", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 265, 1 July 1994 (1994-07-01), pages 103 - 106, XP002933726, ISSN: 0036-8075, DOI: 10.1126/SCIENCE.8016642 * |
JANE BEIL-WAGNER ET AL: "T cell-specific inactivation of mouse CD2 by CRISPR/Cas9", SCIENTIFIC REPORTS, vol. 6, 23 February 2016 (2016-02-23), pages 21377, XP055266212, DOI: 10.1038/srep21377 * |
PANPAN HOU ET AL: "Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection", SCIENTIFIC REPORTS, vol. 5, 20 October 2015 (2015-10-20), pages 15577, XP055267475, DOI: 10.1038/srep15577 * |
SENÍS E ET AL: "CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox", BIOTECHNOLOGY JOURNAL, WILEY-VCH VERLAG, WEINHEIM, DE, vol. 9, no. 11, Sp. Iss. SI, 4 September 2014 (2014-09-04), pages 1402 - 1412, XP002737562, ISSN: 1860-6768, [retrieved on 20141006], DOI: 10.1002/BIOT.201400046 * |
Cited By (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US10508298B2 (en) | 2013-08-09 | 2019-12-17 | President And Fellows Of Harvard College | Methods for identifying a target site of a CAS9 nuclease |
US10954548B2 (en) | 2013-08-09 | 2021-03-23 | President And Fellows Of Harvard College | Nuclease profiling system |
US11920181B2 (en) | 2013-08-09 | 2024-03-05 | President And Fellows Of Harvard College | Nuclease profiling system |
US11046948B2 (en) | 2013-08-22 | 2021-06-29 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US10597679B2 (en) | 2013-09-06 | 2020-03-24 | President And Fellows Of Harvard College | Switchable Cas9 nucleases and uses thereof |
US10682410B2 (en) | 2013-09-06 | 2020-06-16 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
US11299755B2 (en) | 2013-09-06 | 2022-04-12 | President And Fellows Of Harvard College | Switchable CAS9 nucleases and uses thereof |
US10858639B2 (en) | 2013-09-06 | 2020-12-08 | President And Fellows Of Harvard College | CAS9 variants and uses thereof |
US10912833B2 (en) | 2013-09-06 | 2021-02-09 | President And Fellows Of Harvard College | Delivery of negatively charged proteins using cationic lipids |
US9999671B2 (en) | 2013-09-06 | 2018-06-19 | President And Fellows Of Harvard College | Delivery of negatively charged proteins using cationic lipids |
US11053481B2 (en) | 2013-12-12 | 2021-07-06 | President And Fellows Of Harvard College | Fusions of Cas9 domains and nucleic acid-editing domains |
US10465176B2 (en) | 2013-12-12 | 2019-11-05 | President And Fellows Of Harvard College | Cas variants for gene editing |
US11124782B2 (en) | 2013-12-12 | 2021-09-21 | President And Fellows Of Harvard College | Cas variants for gene editing |
US10704062B2 (en) | 2014-07-30 | 2020-07-07 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
US11578343B2 (en) | 2014-07-30 | 2023-02-14 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
US10167457B2 (en) | 2015-10-23 | 2019-01-01 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
US11214780B2 (en) | 2015-10-23 | 2022-01-04 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
US10113163B2 (en) | 2016-08-03 | 2018-10-30 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US10947530B2 (en) | 2016-08-03 | 2021-03-16 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US11702651B2 (en) | 2016-08-03 | 2023-07-18 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
US11306324B2 (en) | 2016-10-14 | 2022-04-19 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
US11820969B2 (en) | 2016-12-23 | 2023-11-21 | President And Fellows Of Harvard College | Editing of CCR2 receptor gene to protect against HIV infection |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
US11932884B2 (en) | 2017-08-30 | 2024-03-19 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
US11697827B2 (en) | 2018-05-16 | 2023-07-11 | Synthego Corporation | Systems and methods for gene modification |
US11802296B2 (en) | 2018-05-16 | 2023-10-31 | Synthego Corporation | Methods and systems for guide RNA design and use |
US11345932B2 (en) | 2018-05-16 | 2022-05-31 | Synthego Corporation | Methods and systems for guide RNA design and use |
US11643652B2 (en) | 2019-03-19 | 2023-05-09 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11795452B2 (en) | 2019-03-19 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11447770B1 (en) | 2019-03-19 | 2022-09-20 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11912985B2 (en) | 2020-05-08 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
CN111909961A (en) * | 2020-08-21 | 2020-11-10 | 华侨大学 | CRISPR/Cas-mediated ATL cell gene editing vector and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017093370A1 (en) | T-cell specific genome editing | |
AU2020286315B2 (en) | Efficient non-meiotic allele introgression | |
Shao et al. | CRISPR/Cas-mediated genome editing in the rat via direct injection of one-cell embryos | |
JP6888213B2 (en) | Simple and highly efficient method for producing genetically modified non-human mammals | |
WO2017104404A1 (en) | Genetic modification non-human organism, egg cells, fertilized eggs, and method for modifying target genes | |
Fujihara et al. | CRISPR/Cas9-based genome editing in mice by single plasmid injection | |
JP2017513510A (en) | Multigene editing in pigs | |
Sato et al. | Timing of CRISPR/Cas9-related mRNA microinjection after activation as an important factor affecting genome editing efficiency in porcine oocytes | |
JP6958917B2 (en) | How to make gene knock-in cells | |
US20190223417A1 (en) | Genetically modified animals having increased heat tolerance | |
US11535850B2 (en) | Methods for improving the health of porcine species by targeted inactivation of CD163 | |
WO2020198541A1 (en) | Porcine reproductive and respiratory syndrome virus (prrsv) resistant swine | |
Leong | An inducible and reversible genetics platform for novel drug target discovery | |
王宪龙 et al. | Efficient CRISPR/Cas9-mediated biallelic gene disruption and site-specific knockin after rapid selection of highly active sgRNAs in pigs | |
NZ718194B2 (en) | Efficient non-meiotic allele introgression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16805386 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16805386 Country of ref document: EP Kind code of ref document: A1 |